174 related articles for article (PubMed ID: 12775016)
1. Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Cho H; Konishi K; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Imada T
Gastric Cancer; 2003; 6 Suppl 1():24-7. PubMed ID: 12775016
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
3. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Takahashi I; Kakeji Y; Emi Y; Sakurai M; Yonemura Y; Kimura Y; Maehara Y
Gastric Cancer; 2003; 6 Suppl 1():28-33. PubMed ID: 12775017
[TBL] [Abstract][Full Text] [Related]
4. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
[TBL] [Abstract][Full Text] [Related]
5. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
Gastric Cancer; 2003; 6 Suppl 1():34-9. PubMed ID: 12775018
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Kawai H; Ohtsu A; Boku N; Hamamoto Y; Nagashima F; Muto M; Sano Y; Mera K; Yano T; Doi T; Yoshida S
Gastric Cancer; 2003; 6 Suppl 1():19-23. PubMed ID: 12775015
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Baba H; Yamamoto M; Endo K; Ikeda Y; Toh Y; Kohnoe S; Okamura T
Gastric Cancer; 2003; 6 Suppl 1():45-9. PubMed ID: 12775020
[TBL] [Abstract][Full Text] [Related]
8. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
[TBL] [Abstract][Full Text] [Related]
9. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
[TBL] [Abstract][Full Text] [Related]
10. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment of gastric cancer accompanied by multiple liver metastases with TS-1 followed by curative gastrectomy affiliation].
Inoue S; Umekita N; Kitamura M
Gan To Kagaku Ryoho; 2002 Jun; 29(6):939-42. PubMed ID: 12090048
[TBL] [Abstract][Full Text] [Related]
13. [A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
Yoshida K; Nishimoto N; Kagawa Y; Hihara J; Inoue H; Kim R; Hirai T; Nishiyama M; Toge T
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1403-12. PubMed ID: 11681248
[TBL] [Abstract][Full Text] [Related]
14. [A case of advanced gastric cancer effectively treated by TS-1 for 4 years].
Ogino H; Misawa T; Nasu T; Ihara Y; Kubo S; Sadamoto Y; Harada N; Nakamura K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):833-6. PubMed ID: 15984526
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
16. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
Oeda M; Hirabayashi N; Takiyama W; Nagamine I; Ohara M; Oshita A; Satou Y; Saeki S; Kirihara Y; Mukaida H; Hisamatu K
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1453-8. PubMed ID: 14584277
[TBL] [Abstract][Full Text] [Related]
18. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
20. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Inaba Y; Watabe S; Ohe S; Kamio Y; Koyama M; Hayashi K; Chiba M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):239-44. PubMed ID: 11865630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
